Cargando…

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of skin/mucosal swelling, and/or attacks of severe abdominal pain when it affects the gastrointestinal tract. The disease might be unexpectedly fatal when the upper airways are compromised. HAE clinical presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petkova, Elena, Yordanova, Vanya, Staevska, Maria, Valerieva, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791933/ https://www.ncbi.nlm.nih.gov/pubmed/36578774 http://dx.doi.org/10.2147/DHPS.S345443

Ejemplares similares

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Therapeutic management of hereditary angioedema: past, present, and future
por: Valerieva, Anna, et al.
Publicado: (2021)

Lanadelumab for hereditary angioedema
Publicado: (2022)

Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE)
por: Parsopoulou, Faidra, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

The physician and hereditary angioedema friend or foe: 62-year diagnostic delay and iatrogenic procedures
por: Valerieva, Anna, et al.
Publicado: (2018)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
por: Fain, Olivier, et al.
Publicado: (2022)

The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews
por: Jean-Baptiste, Milenka, et al.
Publicado: (2022)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
por: Wahn, V., et al.
Publicado: (2012)

Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks
por: Tyson, Christopher, et al.
Publicado: (2019)

Hereditary angioedema (HAE) in Belgium: results from a national survey
por: Van der Poorten, MM, et al.
Publicado: (2023)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022)

Prevention of Recurrent Attacks of Hereditary Angioedema (HAE): Berotralstat and Its Oral Bioavailability
por: Diaz-Menindez, Maximiliano, et al.
Publicado: (2023)

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2022)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

A patient with hereditary angioedema (HAE) with normal C1-INH and SLE with pregnancy
por: Taha, Omar S., et al.
Publicado: (2022)

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry()
por: Valerieva, Anna, et al.
Publicado: (2021)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Screening for hereditary angioedema (HAE) at 13 emergency centers in Osaka, Japan: A prospective observational study
por: Hirose, Tomoya, et al.
Publicado: (2017)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial
por: Javaud, Nicolas, et al.
Publicado: (2016)

Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study()
por: Grumach, Anete S., et al.
Publicado: (2022)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

Treatment of hereditary angioedema with recombinant human C1 Inhibitor in a real-life setting: the experience of the HAE Centre in Milan
por: Zanichelli, Andrea, et al.
Publicado: (2015)

Real-world experience of hereditary angioedema (HAE) in Mexico: A mixed-methods approach to describe epidemiology, diagnosis, and treatment patterns
por: Nieto, Sandra, et al.
Publicado: (2023)

Fluconazole-induced erythema fixum and edema of the upper lip
por: Valerieva, Anna, et al.
Publicado: (2014)

Fast 3: a phase III randomized double-blind, placebo-controlled multicenter study of Icatibant for subcutaneous injection in patients with acute Attacks of Hereditary Angioedema (HAE)
por: Ritchie, B
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_o9mtklv3bmnq6kpf4ebl7go1bl